Foghorn Therapeutics appoints Ryan Maynard as CFO, replacing interim CFO Jeff Sacher

Foghorn Therapeutics Inc.

Ryan Maynard appointed CFO effective February 23, 2026; succeeds Jeff Sacher (interim CFO).
Compensation: $510k base salary, 40% bonus target, $90k signing bonus, 400k share option grant.
Maynard brings 25+ years experience; most recently CFO of Cara Therapeutics (2022-2025).
Previously CFO at Rigel Pharmaceuticals, LetsGetChecked, and Blade Therapeutics; started career at Ernst & Young.
Maynard raised over $1B in financings and executed reverse merger for Cara with Tvardi Therapeutics.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.